Ibrutinib, an orally administered selective inhibitor of BTK, has demonstrated impressive efficacy in the treatment of B cell malignancies and is FDA approved as a therapy for mantle cell lymphoma and chronic lymphocytic leukemia [101, 102]. Here, BTK is linked to mantle cell lymphoma.